naptumomab estafenatox + durvalumab

Naptumomab estafenatox + durvalumab is an investigational combination therapy comprising two immunotherapies. **Naptumomab estafenatox** is a tumor-targeting fusion protein immunotherapy that contains a Fab fragment targeting the 5T4 tumor antigen highly expressed on solid tumors, fused to an engineered bacterial superantigen. This fusion protein activates and redirects T cells to 5T4-expressing tumor cells, resulting in immune infiltration and tumor cell killing[1][3][5][7]. **Durvalumab** is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors, thereby enhancing T cell anti-tumor activity[2][4][6][8]. The combination is being studied as an immunotherapeutic strategy primarily for advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), aiming to synergistically amplify anti-tumor immune responses through direct T cell activation and checkpoint inhibition.

Other names

naptumomab estafenatox + durvalumab